BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 4,000 shares of the business’s stock in a transaction on Friday, April 12th. The shares were sold at an average price of $89.12, for a total transaction of $356,480.00. Following the completion of the sale, the chief executive officer now directly owns 325,211 shares in the company, valued at approximately $28,982,804.32. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Jean Jacques Bienaime also recently made the following trade(s):

  • On Friday, April 5th, Jean Jacques Bienaime sold 3,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $93.37, for a total transaction of $280,110.00.
  • On Monday, April 8th, Jean Jacques Bienaime sold 3,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $91.87, for a total transaction of $275,610.00.
  • On Monday, March 25th, Jean Jacques Bienaime sold 4,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $87.86, for a total transaction of $351,440.00.
  • On Friday, March 15th, Jean Jacques Bienaime sold 4,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $94.40, for a total transaction of $377,600.00.
  • On Tuesday, March 12th, Jean Jacques Bienaime sold 9,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $90.06, for a total transaction of $810,540.00.
  • On Thursday, March 7th, Jean Jacques Bienaime sold 4,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $90.78, for a total transaction of $363,120.00.
  • On Wednesday, February 27th, Jean Jacques Bienaime sold 4,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $91.78, for a total transaction of $367,120.00.
  • On Thursday, February 21st, Jean Jacques Bienaime sold 3,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $90.12, for a total transaction of $270,360.00.
  • On Thursday, February 14th, Jean Jacques Bienaime sold 4,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $95.20, for a total transaction of $380,800.00.
  • On Tuesday, February 5th, Jean Jacques Bienaime sold 4,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $98.63, for a total transaction of $394,520.00.

Shares of NASDAQ:BMRN opened at $91.85 on Tuesday. BioMarin Pharmaceutical Inc. has a 52 week low of $79.13 and a 52 week high of $106.74. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.92 and a current ratio of 3.93. The firm has a market capitalization of $16.04 billion, a PE ratio of -278.33 and a beta of 1.51.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Thursday, February 21st. The biotechnology company reported ($0.02) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.07. BioMarin Pharmaceutical had a negative net margin of 5.18% and a negative return on equity of 2.79%. The company had revenue of $353.00 million for the quarter, compared to the consensus estimate of $377.35 million. During the same quarter in the previous year, the company earned $0.03 EPS. The firm’s revenue for the quarter was down 1.4% compared to the same quarter last year. On average, sell-side analysts forecast that BioMarin Pharmaceutical Inc. will post 0.02 EPS for the current year.

Several brokerages have issued reports on BMRN. Cantor Fitzgerald reissued a “buy” rating and issued a $131.00 price target on shares of BioMarin Pharmaceutical in a report on Tuesday, April 2nd. ValuEngine lowered shares of BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a report on Thursday, March 21st. Raymond James began coverage on shares of BioMarin Pharmaceutical in a report on Tuesday, April 9th. They issued an “outperform” rating and a $110.00 price target on the stock. Zacks Investment Research lowered shares of BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a report on Monday, December 31st. Finally, Robert W. Baird set a $120.00 target price on shares of BioMarin Pharmaceutical and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Two analysts have rated the stock with a sell rating, five have given a hold rating and fifteen have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $114.82.

Several large investors have recently modified their holdings of the company. Dimensional Fund Advisors LP lifted its position in BioMarin Pharmaceutical by 30.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 288,770 shares of the biotechnology company’s stock worth $28,004,000 after buying an additional 66,986 shares in the last quarter. Renaissance Technologies LLC lifted its position in BioMarin Pharmaceutical by 627.0% during the 3rd quarter. Renaissance Technologies LLC now owns 206,971 shares of the biotechnology company’s stock worth $20,070,000 after buying an additional 178,500 shares in the last quarter. Paloma Partners Management Co lifted its position in BioMarin Pharmaceutical by 49.4% during the 3rd quarter. Paloma Partners Management Co now owns 7,356 shares of the biotechnology company’s stock worth $713,000 after buying an additional 2,431 shares in the last quarter. Pacer Advisors Inc. lifted its position in BioMarin Pharmaceutical by 62.4% during the 3rd quarter. Pacer Advisors Inc. now owns 9,180 shares of the biotechnology company’s stock worth $890,000 after buying an additional 3,528 shares in the last quarter. Finally, Point72 Hong Kong Ltd lifted its position in BioMarin Pharmaceutical by 3,524.1% during the 3rd quarter. Point72 Hong Kong Ltd now owns 1,051 shares of the biotechnology company’s stock worth $102,000 after buying an additional 1,022 shares in the last quarter.

ILLEGAL ACTIVITY NOTICE: This report was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.thecerbatgem.com/2019/04/16/biomarin-pharmaceutical-inc-bmrn-ceo-jean-jacques-bienaime-sells-4000-shares.html.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Read More: SEC Filing

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.